Literature DB >> 3279822

Cardiovascular performance with E. coli challenges in a canine model of human sepsis.

C Natanson1, R L Danner, M P Fink, T J MacVittie, R I Walker, J J Conklin, J E Parrillo.   

Abstract

We investigated cardiovascular dysfunction by injecting lethal and nonlethal bacterial challenges into conscious dogs. E. coli bacteria of varying numbers were placed in a peritoneal clot. Cardiovascular function was studied with simultaneous radionuclide scans and thermodilution cardiac outputs. In surviving animals, the number of bacteria in the clot increased as the corresponding systolic cardiac function decreased (P = 0.01). Cardiac function was measured by left ventricular (LV) ejection fraction (EF) and LV function curves [LV stroke work index (LVSWI) vs. end-diastolic volume index (EDVI), and peak systolic pressure vs. end-systolic volume index]. Furthermore, the diastolic volume-pressure relationship of survivors shifted progressively to the right [i.e., increasing EDVI (P less than 0.02) with minimal change (P = NS) in LV filling pressure]. This increase in LV size was associated with maintenance of measures of cardiac performance [stroke volume index (SVI) and stroke work index (SWI)] at similar levels. Death occurred only in the group with the highest bacterial dose. Compared with survivors receiving the same number of bacteria, nonsurvivors had a decrease in (P less than 0.05) LV size, a leftward shift (P less than 0.01) in LV diastolic volume-pressure relationship, and a decrease in both LVSWI and SVI (possibly related to volume and/or LV functional status). Data from survivors suggest that increasing the number of bacteria produces changes in myocardial compliance and contractility. These changes increase LV size (preload), a major determinant of cardiac performance that possibly enhances survival.

Entities:  

Mesh:

Year:  1988        PMID: 3279822     DOI: 10.1152/ajpheart.1988.254.3.H558

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Septic shock: a heart story since the 1960s.

Authors:  C Rabuel; A Mebazaa
Journal:  Intensive Care Med       Date:  2006-03-29       Impact factor: 17.440

2.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 3.  Modeling sepsis in the laboratory: merging sound science with animal well-being.

Authors:  Jean A Nemzek; Kelly M S Hugunin; Mark R Opp
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

Review 4.  Cardiac dysfunction in sepsis: new theories and clinical implications.

Authors:  R M Grocott-Mason; A M Shah
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

5.  Inotropic response to endothelin-1, isoprenaline and calcium in cardiomyocytes isolated from endotoxin treated rats: effects of ethyl-isothiourea and dexamethasone.

Authors:  J P Spiers; E J Kelso; J D Allen; B Silke; B J McDermott
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.

Authors:  C Natanson; R L Danner; R J Elin; J M Hosseini; K W Peart; S M Banks; T J MacVittie; R I Walker; J E Parrillo
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

7.  N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin.

Authors:  J P Cobb; C Natanson; W D Hoffman; R F Lodato; S Banks; C A Koev; M A Solomon; R J Elin; J M Hosseini; R L Danner
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

Review 8.  Preclinical septic shock research: why we need an animal ICU.

Authors:  Antoine Guillon; Sebastien Preau; Jérôme Aboab; Eric Azabou; Boris Jung; Stein Silva; Julien Textoris; Fabrice Uhel; Dominique Vodovar; Lara Zafrani; Nicolas de Prost; Peter Radermacher
Journal:  Ann Intensive Care       Date:  2019-06-10       Impact factor: 6.925

9.  Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum.

Authors:  A Kumar; V Thota; L Dee; J Olson; E Uretz; J E Parrillo
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock.

Authors:  C Natanson; P W Eichenholz; R L Danner; P Q Eichacker; W D Hoffman; G C Kuo; S M Banks; T J MacVittie; J E Parrillo
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.